ACCREDO

Accredo Health, Incorporated provides specialized pharmacy andrelated services pursuant to agreements with biotechnology drugmanufacturers relating to the treatment of patients with certaincostly, chronic diseases. The Company´s services include collection oftimely drug utilization and patient compliance information, patienteducation and monitoring through the use of written materials andtelephonic consultation, reimbursement expertise and overnight drugdelivery.
Certain of the statements in the preceding paragraphs,particularly those anticipating future financial performance andbusiness prospects, constitute forward-looking statements within themeaning of the "safe harbor" provisions of the Private SecuritiesLitigation Reform Act of 1995. Such statements may be identified bywords such as anticipate, believe, could, estimate, expect, intend,predict, hope or similar expressions. Such statements, which includeestimated financial information or results, are based on management´scurrent expectations and are subject to a number of factors anduncertainties which could cause actual results to differ materiallyfrom those described in the forward-looking statements, including,without limitation, the uncertainty as to the outcome of anylitigation, the loss of a biopharmaceutical relationship, ourinability to sell existing products, difficulties integrating the SPSdivision, the impact of pharmaceutical industry regulation, thedifficulty of predicting FDA and other regulatory authority approvals,the regulatory environment and changes in healthcare policies andstructure, acceptance and demand for new pharmaceutical products andnew therapies, the impact of competitive products and pricing, theability to obtain products from suppliers, reliance on strategicalliances, the ability to expand through joint ventures andacquisitions, the ability to maintain pricing arrangements withsuppliers that preserve margins, the need for and ability to obtainadditional capital, the seasonality and variability of operatingresults, the Company´s ability to implement its strategies and achieveits objectives and the risks and uncertainties described in reportsfiled by Accredo with the Securities and Exchange Commission under theSecurities Exchange Act of 1934, as amended, including withoutlimitation, cautionary statements under the heading "Risk Factors"made in Accredo´s 2002 Annual Report on Form 10-K.

--30--DH/na* CONTACT: Accredo Health, Incorporated, Memphis Financial Contact: Joel Kimbrough, 901/385-3621 or Investor Relations Contact: Kerry Finney, 901/381-7442 KEYWORD: TENNESSEE INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY MARKETINGAGREEMENTS SOURCE: Accredo Health, Incorporated

(c) 2003 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

Unlike emphysema that develops as a result of smoke inhalation,hereditary emphysema caused by Alpha-1 deficiency is a condition thatmay affect both the structure and the function of the lungs.Individuals as young as thirty years of age may be affected, and ifthe condition is left untreated, Alpha-1 can be fatal.
Accredo Health, Incorporated provides specialized pharmacy andrelated services pursuant to agreements with biotechnology drugmanufacturers relating to the treatment of patients with certaincostly, chronic diseases. The Company´s services include collection oftimely drug utilization and patient compliance information, patienteducation and monitoring through the use of written materials andtelephonic consultation, reimbursement expertise and overnight drugdelivery.
Certain of the statements in the preceding paragraphs,particularly those anticipating future financial performance andbusiness prospects, constitute forward-looking statements within themeaning of the "safe harbor" provisions of the Private SecuritiesLitigation Reform Act of 1995. Such statements may be identified bywords such as anticipate, believe, could, estimate, expect, intend,predict, hope or similar expressions. Such statements, which includeestimated financial information or results, are based on management´scurrent expectations and are subject to a number of factors anduncertainties which could cause actual results to differ materiallyfrom those described in the forward-looking statements, including,without limitation, the uncertainty as to the outcome of anylitigation, the loss of a biopharmaceutical relationship, ourinability to sell existing products, difficulties integratingacquisitions, the impact of pharmaceutical industry regulation, thedifficulty of predicting FDA and other regulatory authority approvals,the regulatory environment and changes in healthcare policies andstructure, acceptance and demand for new pharmaceutical products andnew therapies, the impact of competitive products and pricing, theability to obtain products from suppliers, reliance on strategicalliances, the ability to expand through joint ventures andacquisitions, the ability to maintain pricing arrangements withsuppliers that preserve margins, the need for and ability to obtainadditional capital, the seasonality and variability of operatingresults, the Company´s ability to implement its strategies and achieveits objectives and the risks and uncertainties described in reportsfiled by Accredo with the Securities and Exchange Commission under theSecurities Exchange Act of 1934, as amended, including withoutlimitation, cautionary statements under the heading "Risk Factors"made in Accredo´s 2002 Annual Report on Form 10-K and its most recent10-Q.
Note to editors: For information about Aventis Behring orZemaira(TM), please contact Kim Cayz at 1-610-878-4822 orkim.cayz@aventis.com.

--30--JB/na* CONTACT: Accredo Health Inc., Memphis Financial: Joel Kimbrough, 901-385-3621 or Investor Relations: Kerry Finney, 901-381-7442 KEYWORD: TENNESSEE INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY MARKETINGAGREEMENTS PRODUCT SOURCE: Accredo Health, Incorporated

(c) 2003 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

Im Gegensatz zu Emphysem, das sich in Folge von Rauchinhalation entwickelt, ist von Alpha-1 Mangel verursachtes erbliches Emphysem eine Kondition, die sowohl die Struktur als auch die Funktion der Lungen beeinflussen kann. Es kann sein, daß Personen, so jung wie dreißig Jahre des Alters, betroffen sind, und, wenn die Kondition nach links unbehandelt ist, kann Alpha-1 tödlich sein.

Accredo Gesundheit, integrierte liefert spezialisierter Apotheke und verwandten Dienstleistungen entsprechend Vereinbarungen mit Biotechnikmedikamentenherstellern sich Beziehen auf die Behandlung von Patienten mit bestimmten kostspieligen, chronischen Krankheiten. Die Dienstleistungen des Unternehmens schließen Sammlung von rechtzeitiger Medikamentenverwendung und geduldiger Einhaltungsinformation, geduldige Bildung und Überwachung durch die Verwendung der schriftlichen Materialien und der telefonischen Beratung, Erstattungssachkenntnis und Nachtmedikamentenlieferung ein.

Reuters
Accredo 4th-qtr profitieren hinauf scharf
Donnerstags4. September, 6:39 a.m. ET


New York, 4. sept (Reuters) - Accredo Health Inc. (NasdaqNM: ACDO - Nachrichten), welches verteilt Medikamente an Patienten mit chronischen Krankheiten, auf Donnerstag sagte, daß sein vierteljährlicher Gewinn scharf anstieg, nachdem ein Erwerb ihm eine breitere Produktpalette gab.
Nettoeinkommen für das Juni 30 beendete Finanzvierte Viertel stieg auf $ 17,2 Millionen oder 36 Cents pro Anteil von ein Anteil $ 7,7 Millionen oder 18 Cents ein Jahr früher an.

Reuters Forschung gab Konsensverdienste pro Anteilsschätzungen von 32 Cents heraus.

Das Unternehmen, das vor kurzem Gentiva Gesundheitswesen kaufte, ' (NasdaqNM: GTIV - Nachrichten) das Spezialitätenapothekengeschäft, leicht hob seine Einnahme- und Verdienstvorhersagen für den Finanzjahrausgang im Juni 2004 an.